Loading...

DiaMedica Therapeutics

BST:F2K
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
F2K
BST
CA$1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The last earnings update was 78 days ago. More info.


Add to Portfolio Compare Print
  • DiaMedica Therapeutics has significant price volatility in the past 3 months.
F2K Share Price and Events
7 Day Returns
-18%
BST:F2K
-3.4%
DE Biotechs
-1.4%
DE Market
1 Year Returns
4.1%
BST:F2K
4.8%
DE Biotechs
-8.2%
DE Market
F2K Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
DiaMedica Therapeutics (F2K) -18% -34.9% -27.6% 4.1% - -
DE Biotechs -3.4% -2.6% -10.2% 4.8% 64.7% 72.6%
DE Market -1.4% 0.3% -5.6% -8.2% 26.6% 48.8%
1 Year Return vs Industry and Market
  • F2K outperformed the Market in Germany which returned -8.2% over the past year.
Price Volatility
F2K
Industry
5yr Volatility vs Market
Related Companies

F2K Value

 Is DiaMedica Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for DiaMedica Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €0.228.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for DiaMedica Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are DiaMedica Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:F2K PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in USD $-0.04
TSXV:DMA Share Price ** TSXV (2018-11-14) in CAD CA$6.1
TSXV:DMA Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.757 $4.62
Europe Biotechs Industry PE Ratio Median Figure of 25 Publicly-Listed Biotechs Companies 28.85x
Germany Market PE Ratio Median Figure of 415 Publicly-Listed Companies 17.94x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of DiaMedica Therapeutics.

BST:F2K PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:DMA Share Price ÷ EPS (both in USD)

= 4.62 ÷ -0.04

-103.52x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DiaMedica Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • DiaMedica Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does DiaMedica Therapeutics's expected growth come at a high price?
Raw Data
BST:F2K PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -103.52x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
71.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 16 Publicly-Listed Biotechs Companies 1.56x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.39x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for DiaMedica Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on DiaMedica Therapeutics's assets?
Raw Data
BST:F2K PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in USD $0.01
TSXV:DMA Share Price * TSXV (2018-11-14) in CAD CA$6.1
TSXV:DMA Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.757 $4.62
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.32x
Germany Market PB Ratio Median Figure of 553 Publicly-Listed Companies 1.88x
BST:F2K PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:DMA Share Price ÷ Book Value per Share (both in USD)

= 4.62 ÷ 0.01

493.81x

* Primary Listing of DiaMedica Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DiaMedica Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess DiaMedica Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. DiaMedica Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

F2K Future Performance

 How is DiaMedica Therapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
71.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is DiaMedica Therapeutics expected to grow at an attractive rate?
  • DiaMedica Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • DiaMedica Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare DiaMedica Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:F2K Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:F2K Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 71.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 50.9%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:F2K Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:F2K Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 58 28 1
2021-12-31 35 19 1
2020-12-31 12 1 1
2019-12-31 0 -7 1
2018-12-31 0 -4 1
BST:F2K Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-06-30 -4 -6
2018-03-31 -4 -3
2017-12-31 -4 -4
2017-09-30 -4 -4
2017-06-30 -4 -4
2017-03-31 -3 -3
2016-12-31 -3 -2
2016-09-30 -2 -2
2016-06-30 -2 -2
2016-03-31 -2 -1
2015-12-31 -2 -2
2015-09-30 -1 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • DiaMedica Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if DiaMedica Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:F2K Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from DiaMedica Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:F2K Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 3.08 3.08 3.08 1.00
2021-12-31 2.19 2.19 2.19 1.00
2020-12-31 0.15 0.15 0.15 1.00
2019-12-31 -0.78 -0.78 -0.78 1.00
2018-12-31 -0.46 -0.46 -0.46 1.00
BST:F2K Past Financials Data
Date (Data in USD Millions) EPS *
2018-06-30 -0.04
2018-03-31 -0.03
2017-12-31 -0.04
2017-09-30 -0.03
2017-06-30 -0.03
2017-03-31 -0.03
2016-12-31 -0.02
2016-09-30 -0.03
2016-06-30 -0.02
2016-03-31 -0.02
2015-12-31 -0.02
2015-09-30 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if DiaMedica Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess DiaMedica Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
DiaMedica Therapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

F2K Past Performance

  How has DiaMedica Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare DiaMedica Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • DiaMedica Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare DiaMedica Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare DiaMedica Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
DiaMedica Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from DiaMedica Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:F2K Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 -5.94 1.93 2.29
2018-03-31 -3.45 1.21 2.16
2017-12-31 -4.18 0.90 3.27
2017-09-30 -3.72 0.74 3.00
2017-06-30 -3.76 0.74 3.25
2017-03-31 -3.20 0.73 2.69
2016-12-31 -2.22 0.72 1.76
2016-09-30 -2.39 0.75 1.66
2016-06-30 -1.68 0.56 1.07
2016-03-31 -1.49 0.49 0.91
2015-12-31 -1.59 0.47 0.98
2015-09-30 -1.75 0.56 1.10
2015-06-30 -2.42 0.71 1.42
2015-03-31 -3.09 0.83 1.99
2014-12-31 -4.83 1.12 3.44
2014-09-30 -5.39 0.95 4.12
2014-06-30 -6.00 0.97 4.99
2014-03-31 -6.68 0.93 5.71
2013-12-31 -7.43 0.90 6.50
2013-09-30 -9.18 0.89 8.32
2013-06-30 -10.08 1.01 9.12
2013-03-31 -10.76 1.27 9.50
2012-12-31 -10.03 1.17 8.90
2012-09-30 -8.97 1.21 7.79
2012-06-30 -7.97 1.28 6.70
2012-03-31 -7.02 0.96 6.09
2011-12-31 -6.64 0.97 5.71

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if DiaMedica Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if DiaMedica Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if DiaMedica Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess DiaMedica Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
DiaMedica Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

F2K Health

 How is DiaMedica Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up DiaMedica Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • DiaMedica Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • DiaMedica Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of DiaMedica Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • DiaMedica Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from DiaMedica Therapeutics Company Filings, last reported 4 months ago.

BST:F2K Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 1.46 0.00 5.66
2018-03-31 4.73 0.00 6.72
2017-12-31 0.79 0.00 1.36
2017-09-30 -0.03 0.00 0.86
2017-06-30 0.73 0.00 1.53
2017-03-31 0.01 0.00 0.94
2016-12-31 1.25 0.00 1.74
2016-09-30 1.62 0.48 2.97
2016-06-30 -1.04 0.68 0.36
2016-03-31 -1.01 0.41 0.33
2015-12-31 -1.23 0.65 0.17
2015-09-30 -1.15 0.46 0.14
2015-06-30 -0.94 0.88 0.46
2015-03-31 -1.38 1.02 0.27
2014-12-31 -1.53 0.00 0.20
2014-09-30 -0.71 0.00 0.49
2014-06-30 0.09 0.00 1.25
2014-03-31 -0.40 0.00 1.47
2013-12-31 1.38 0.00 2.53
2013-09-30 0.52 0.00 1.07
2013-06-30 1.59 0.00 2.08
2013-03-31 3.58 0.00 4.34
2012-12-31 2.26 0.00 2.34
2012-09-30 5.14 0.00 3.88
2012-06-30 5.58 0.00 3.91
2012-03-31 4.52 0.00 2.07
2011-12-31 5.99 0.00 2.66
  • DiaMedica Therapeutics has no debt.
  • DiaMedica Therapeutics had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • DiaMedica Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • DiaMedica Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 24.5% each year.
X
Financial health checks
We assess DiaMedica Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. DiaMedica Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

F2K Dividends

 What is DiaMedica Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from DiaMedica Therapeutics dividends.
If you bought €2,000 of DiaMedica Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate DiaMedica Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate DiaMedica Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:F2K Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:F2K Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as DiaMedica Therapeutics has not reported any payouts.
  • Unable to verify if DiaMedica Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of DiaMedica Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as DiaMedica Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess DiaMedica Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can DiaMedica Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. DiaMedica Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

F2K Management

 What is the CEO of DiaMedica Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rick Pauls
COMPENSATION $487,427
AGE 47
TENURE AS CEO 9.3 years
CEO Bio

Mr. Rick Pauls, MBA has been Chief Executive Officer and President of Diamedica Inc. since July 31, 2009. Mr. Pauls was an Executive of GMAC Residential Funding of Canada Ltd. He served as the President of Sanomune Inc. He served as Managing Director of CentreStone Ventures Inc., the General Partner of CentreStone Ventures LP since February 2002. He was involved in all aspects of the management of CentreStone. He served as Chief Executive Officer and President of Diamedica Inc. from 2009 to 2010. He served as Acting Chief Executive Officer of Diamedica Inc. since July 31, 2009 until June 29, 2010. He served as the Chief Executive Officer and President of Diamedica Inc. until February 9, 2009. He served as Interim President and Interim Chief Executive Officer of Diamedica Inc. since April 8, 2008 and its Secretary since April 2005. He served as the Director of Venture Finance at Genesys Venture Inc. He served as an Analyst from August 1999 to February 2001 at Centara Corporation. Mr. Pauls has also worked in business development roles for both private and public life sciences and information technology companies. He was with General Motors Acceptance Corporation in Minneapolis, Minnesota, where he specialized in asset-backed securitization and structured finance. He served as the Chairman of Diamedica Inc. from April 8, 2008 to July 7, 2014 and has been its Director since April 2005. He serves as a Director of TechStars, LLC., Verista Imaging, Inc. and LED Dental, Inc. He served as an Independent Director of LED Medical Diagnostics, Inc. since October 15, 2008 until August 22, 2017. He served as a Director of Orasi Medical, Inc. Mr. Pauls received his Bachelor of Arts in Economics from the University of Manitoba and his M.B.A. in Finance from the University of North Dakota.

CEO Compensation
  • Rick's compensation has increased whilst company is loss making.
  • Rick's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the DiaMedica Therapeutics management team in years:

2.3
Average Tenure
55
Average Age
  • The tenure for the DiaMedica Therapeutics management team is about average.
Management Team

Rick Pauls

TITLE
CEO, President & Director
COMPENSATION
$487K
AGE
47
TENURE
9.3 yrs

Todd Verdoorn

TITLE
Chief Scientific Officer
COMPENSATION
$337K
AGE
57
TENURE
2.5 yrs

Scott Kellen

TITLE
CFO & Company Secretary
AGE
53
TENURE
0.6 yrs

Ed Rady

TITLE
Chief Commercial Advisor
AGE
69
TENURE
3.1 yrs

Dennis Kim

TITLE
Consulting Chief Medical Officer
COMPENSATION
$12K
AGE
48
TENURE
5.6 yrs

Harry Alcorn

TITLE
Chief Medical Officer
AGE
62
TENURE
0.2 yrs

Paul Papi

TITLE
Vice President of Business Development
TENURE
1.9 yrs

Mark Williams

TITLE
Consultant
COMPENSATION
$182K
TENURE
2 yrs
Board of Directors Tenure

Average tenure and age of the DiaMedica Therapeutics board of directors in years:

3.1
Average Tenure
57
Average Age
  • The tenure for the DiaMedica Therapeutics board of directors is about average.
Board of Directors

Rich Pilnik

TITLE
Chairman
COMPENSATION
$52K
AGE
61
TENURE
4.3 yrs

Rick Pauls

TITLE
CEO, President & Director
COMPENSATION
$487K
AGE
47
TENURE
13.6 yrs

R. Giuffre

TITLE
Director
COMPENSATION
$36K
AGE
62
TENURE
8.3 yrs

James Parsons

TITLE
Director
COMPENSATION
$36K
AGE
53
TENURE
3.1 yrs

Jerry Xiao

TITLE
Director
COMPENSATION
$36K
AGE
44
TENURE
2 yrs

Philip Bath

TITLE
Member of Scientific Advisory Board

Paolo Madeddu

TITLE
Member of Scientific Advisory Board

John Volpi

TITLE
Member of Scientific Advisory Board

Nancy Chang

TITLE
Member of Strategic Advisory Board
AGE
68
TENURE
1.6 yrs

Robert Stanton

TITLE
Member of Kidney Scientific Advisory Board
TENURE
1.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Start End Shares Max Price (€) Value (€)
02. Aug 18 Buy Todd Verdoorn Individual 31. Jul 18 01. Aug 18 20,000 €0.30 €5,966.31
12. Jul 18 Buy Scott Kellen Individual 29. Mar 18 29. Mar 18 40,800 €0.20 €7,970.72
12. Jul 18 Buy Rick Pauls Individual 29. Mar 18 29. Mar 18 82,000 €0.20 €16,019.58
12. Jul 18 Buy R. Giuffre Individual 29. Mar 18 29. Mar 18 408,164 €0.20 €79,739.22
X
Management checks
We assess DiaMedica Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. DiaMedica Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

F2K News

External News
Loading...
Simply Wall St News

F2K Company Info

Map
Description

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company’s lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Details
Name: DiaMedica Therapeutics Inc.
F2K
Exchange: BST
Founded: 2000
CA$725,316,182
157,137,509
Website: http://www.diamedica.com
Address: DiaMedica Therapeutics Inc.
Two Carlson Parkway,
Suite 260,
Minneapolis,
Minnesota, 55447,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV DMA Common Shares TSX Venture Exchange CA CAD 22. Mar 2007
OTCPK DMCA.F Common Shares Pink Sheets LLC US USD 22. Mar 2007
BST F2K Common Shares Boerse-Stuttgart DE EUR 22. Mar 2007
Number of employees
Current staff
Staff numbers
10
DiaMedica Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/11/15 22:04
End of day share price update: 2018/11/14 00:00
Last estimates confirmation: 2018/08/27
Last earnings filing: 2018/08/29
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.